SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G,Rogers B,Ross R,Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 23352342.
  • 2
    Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987989.
  • 3
    Auerbach R,Lewis R,Shinners B,Kubai L,Akhtar N. Angiogenesis assays: A critical overview. Clin Chem 2003; 49: 3240.
  • 4
    Tran TC,Sneed B,Haider J,Blavo D,White A,Aiyejorun T,Baranowski TC,Rubinstein AL,Doan TN,Dingledine R,Sandberg EM. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 2007; 67: 1138611392.
  • 5
    Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006; 10: 588612.
  • 6
    Evensen L,Micklem DR,Blois A,Berge SV,Aarsaether N,Littlewood-Evans A,Wood J,Lorens JB. Mural cell associated VEGF is required for organotypic vessel formation. PLoS One 2009; 4: e5798.
  • 7
    Evensen L,Micklem DR,Blois A,Littlewood-Evans A,Wood J,Lorens JB. Mural cell associated VEGF is required for organotypic vessel formation. PlosOne 2009; vol 4 (6).
  • 8
    Evensen L,Micklem DR,Blois A,Vik-Berge S,Aarsæther N,Littlewood-Evans A,Wood J,Lorens JB. Mural cells regulate temporal endothelial VEGF-dependency and therapeutic resistance. In press.
  • 9
    Evensen L,Micklem DR,Blois A,Littlewood-Evans A,Wood J,Altmann KH,Odlo K,Hansen TV,Lorens JB. A biphasic profiling approach to discriminate normalizing and vascular disrupting agents. In press.
  • 10
    Wood JM,Bold G,Buchdunger E,Cozens R,Ferrari S,Frei J,Hofmann F,Mestan J,Mett H,O'Reilly T,Persohn E,Rösel J,Schnell C,Stover D,Theuer A,Towbin H,Wenger F,Woods-Cook K,Menrad A,Siemeister G,Schirner M,Thierauch KH,Schneider MR,Drevs J,Martiny-Baron G,Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 21782189.
  • 11
    Lee SH,Lopes De Menezes D,Vora J,Harris A,Ye H,Nordahl L,Garrett E,Samara E,Aukerman SL,Gelb AB,Heise C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005; 11: 36333641.
  • 12
    Kuzniewski CN,Gertsch J,Wartmann M,Altmann KH. Total synthesis of hypermodified epothilone analogs with potent in vitro antitumor activity. Org Lett 2008; 10: 11831186.
  • 13
    Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417421.
  • 14
    Swift S,Lorens J,Achacoso P,Nolan GP. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol 2001; Unit 10: 17C.
  • 15
    Lorens JB,Bennett MK,Pearsall DM,Throndset WR,Rossi AB,Armstrong RJ,Fox BP,Chan EH,Luo Y,Masuda E,Ferrick DA,Anderson DC,Payan DG,Nolan GP. Retroviral delivery of peptide modulators of cellular functions. Mol Ther 2000; 1 (Part 1): 438447.
  • 16
    Shaner NC,Campbell RE,Steinbach PA,Giepmans BN,Palmer AE,Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004; 22: 15671572.
  • 17
    Pettit GR,Singh SB,Hamel E,Lin CM,Alberts DS,Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45: 209211.
  • 18
    Dark GG,Hill SA,Prise VE,Tozer GM,Pettit GR,Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 18291834.
  • 19
    Chaplin DJ,Pettit GR,Parkins CS,Hill SA. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer Suppl 1996; 27: S86S88.
  • 20
    Zanella F,Rosado A,Blanco F,Henderson BR,Carnero A,Link W. An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol 2007; 5: 333341.
  • 21
    Rai SS,Wolff J. Localization of the vinblastine-binding site on beta-tubulin. J Biol Chem 1996; 271: 1470714711.
  • 22
    Ribatti D,Guidolin D,Conconi MT,Nico B,Baiguera S,Parnigotto PP,Vacca A,Nussdorfer GG. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene 2003; 22: 64586461.
  • 23
    Fujita K,Sano D,Kimura M,Yamashita Y,Kawakami M,Ishiguro Y,Nishimura G,Matsuda H,Tsukuda M. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2007; 18: 4751.
  • 24
    Kimura N,Mikami K,Nakamura N,Endoh H. Alteration of developmental program in Paramecium by treatment with trichostatin a: A possible involvement of histone modification. Protist 2006; 157: 303314.
  • 25
    Rossig L,Li H,Fisslthaler B,Urbich C,Fleming I,Forstermann U,Zeiher AM,Dimmeler S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002; 91: 837844.
  • 26
    Kim MS,Kwon HJ,Lee YM,Baek JH,Jang JE,Lee SW,Moon EJ,Kim HS,Lee SK,Chung HY,Kim CW,Kim KY. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437443.
  • 27
    Deroanne CF,Bonjean K,Servotte S,Devy L,Colige A,Clausse N,Blacher S,Verdin E,Foidart JM,Nusgens BV,Castronovo V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21: 427436.
  • 28
    Shukla N,Freeman N,Gadsdon P,Angelini GD,Jeremy JY. Thapsigargin inhibits angiogenesis in the rat isolated aorta: Studies on the role of intracellular calcium pools. Cardiovasc Res 2001; 49: 681689.
  • 29
    Takadera T,Ohyashiki T. Calmodulin inhibitor-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells. Cell Mol Neurobiol 2007; 27: 783790.
  • 30
    Sui Y,Wu Z. Alternative statistical parameter for high-throughput screening assay quality assessment. J Biomol Screen 2007; 12: 229234.
  • 31
    Korff T,Kimmina S,Martiny-Baron G,Augustin HG. Blood vessel maturation in a 3-dimensional spheroidal co-culture model: Direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 2001; 15: 447457.
  • 32
    Dhamodharan R,Jordan MA,Thrower D,Wilson L,Wadsworth P. Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol Biol Cell 1995; 6: 12151229.
  • 33
    Grigoriev IS,Chernobelskaya AA,Vorobjev IA. Nocodazole, vinblastine and taxol at low concentrations affect fibroblast locomotion and saltatory movements of organelles. Membr Cell Biol 1999; 13: 2348.
  • 34
    Wang J,Lou P,Lesniewski R,Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003; 14: 1319.
  • 35
    Heydarkhan-Hagvall S,Helenius G,Johansson BR,Li JY,Mattsson E,Risberg B. Co-culture of endothelial cells and smooth muscle cells affects gene expression of angiogenic factors. J Cell Biochem 2003; 89: 12501259.
  • 36
    Kohn EC,Alessandro R,Spoonster J,Wersto RP,Liotta LA. Angiogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 1995; 92: 13071311.
  • 37
    Shukla N,Jeremy JY,Nicholl P,Krijgsman B,Stansby G,Hamilton G. Short-term exposure to low concentrations of thapsigargin inhibits replication of cultured human vascular smooth muscle cells. Br J Surg 1997; 84: 325330.
  • 38
    Birkett SD,Jeremy JY,Watts SM,Shukla N,Angelini GD,Mcardle CA. Inhibition of intracellular Ca2+ mobilisation by low antiproliferative concentrations of thapsigargin in human vascular smooth-muscle cells. J Cardiovasc Pharmacol 1999; 33: 204211.